利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.024 秒)

    ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION
    5.
    发明申请
    ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION 审中-公开
    抗ADRENOMEDULLIN（ADM）抗体或抗体抗体片段或抗ADM NON-IG SCAFFOLD用于预防或减少患有慢性或急性疾病或急性疾病的患者的器官功能障碍或器官失败

    公开(公告)号：US20140328853A1

    公开(公告)日：2014-11-06

    申请号：US14358334

    申请日：2012-11-16

    申请人： ADRENOMED AG

    发明人： Andreas Bergmann

    IPC分类号： C07K16/26 ,  A61K31/137 ,  A61K38/22

    摘要： Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

    摘要翻译： 本发明的主题是用于治疗患者的慢性或急性疾病或急性病症的抗肾上腺髓质素（ADM）抗体或抗肾上腺髓质素抗体片段或抗ADM非Ig支架，用于预防或 减少器官功能障碍或器官衰竭。 在一个优选的实施方案中，本发明的主题是用于治疗患者的慢性或急性疾病或急性病症的抗ADM抗体或抗肾上腺髓质素抗体片段或抗-ADM非Ig支架，用于预防或减少 的肾功能不全或肾衰竭或肝功能障碍或肝衰竭。

    Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
    8.
    发明授权
    Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy 有权
    抗肾上腺髓质素（ADM）抗体或抗ADM抗体片段用于治疗

    公开(公告)号：US09304127B2

    公开(公告)日：2016-04-05

    申请号：US13679294

    申请日：2012-11-16

    申请人： ADRENOMED AG

    发明人： Andreas Bergmann

    IPC分类号： A61K39/395 ,  C07K16/22 ,  G01N33/543 ,  C07K16/26 ,  G01N33/68 ,  A61K31/137 ,  A61K38/17 ,  A61K45/06 ,  C07K16/18 ,  A61K39/00

    CPC分类号： G01N33/54306 ,  A61K31/137 ,  A61K38/1725 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6893 ,  G01N2800/52 ,  G01N2800/7095

    摘要： Subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-Ig scaffold, respectively. Subject matter of the present invention is also in anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in a treatment of a chronic or acute disease wherein said antibody or fragment or scaffold is an ADM stabilizing antibody or an adrenomedullin stabilizing antibody fragment or an ADM stabilizing non-Ig scaffold that enhances the t½ half retention time of adrenomedullin in serum, blood, plasma at least 10%, preferably at least, 50%, more preferably >50%, most preferably 100%, and/or wherein said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold blocks the bioactivity of ADM to not more than 80%, or not more than 50%.

    摘要翻译： 本发明的主题是抗肾上腺髓质素抗体或抗肾上腺髓质素抗体片段或抗ADM非Ig支架，其中所述抗体或所述片段或支架是非中和抗体，抗体片段或非Ig支架， 分别。 本发明的主题还在用于治疗慢性或急性疾病的抗肾上腺髓质素抗体或抗肾上腺髓质素抗体片段或抗-ADM非Ig支架中，其中所述抗体或片段或支架是ADM稳定 抗体或肾上腺髓质素稳定抗体片段或ADM稳定化非Ig支架，其增强肾上腺髓质素在血清，血液，血浆中的半衰期半衰期至少10％，优选至少50％，更优选> 50％，最优选地 和/或其中所述抗ADM抗体或抗肾上腺髓质素抗体片段或抗ADM非Ig支架将ADM的生物活性阻断至不大于80％或不超过50％。

    Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
    9.
    发明授权
    Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition 有权
    抗肾上腺髓质素（ADM）抗体或抗ADM抗体片段或抗ADM非IG支架，用于降低患有慢性或急性疾病或急性病症的患者的死亡风险

    公开(公告)号：US09140696B2

    公开(公告)日：2015-09-22

    申请号：US13679281

    申请日：2012-11-16

    申请人： ADRENOMED AG

    发明人： Andreas Bergmann

    IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  G01N33/543 ,  C07K16/26 ,  G01N33/68 ,  A61K31/137 ,  A61K38/17 ,  A61K45/06 ,  C07K16/18

    CPC分类号： G01N33/54306 ,  A61K31/137 ,  A61K38/1725 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6893 ,  G01N2800/52 ,  G01N2800/7095

    摘要： According to the present invention it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present invention said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM that is located in the N-terminal part (aa 1-21) of adrenomedullin, (see FIG. 2). In another preferred embodiment said anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold recognizes and binds to the N-terminal end (aa1) of adrenomedullin. N-terminal end means that the amino acid 1, that is “Y” of SEQ ID No. 21 or 23, is mandatory for antibody binding. The anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold would neither bind N-terminal extended nor N-terminal modified Adrenomedullin nor N-terminal degraded Adrenomedullin in said preferred embodiment.

    摘要翻译： 根据本发明，已经发现，施用抗ADM抗体或抗肾上腺髓质素抗体片段或抗ADM非Ig支架可显着降低具有严重慢性或急性的患者的死亡风险 疾病。 在本发明的优选实施方案中，所述抗ADM抗体或抗肾上腺髓质素抗体片段或抗-ADM非Ig支架结合位于N末端部分（aa 1-21）中的ADM区域 肾上腺髓质素（参见图2）。 在另一个优选的实施方案中，所述抗ADM抗体或抗ADM片段或抗-ADM非Ig支架识别并结合肾上腺髓质素的N末端（aa1）。 N-末端表示SEQ ID No.21或23的氨基酸1，即“Y”是抗体结合所必需的。 在所述优选实施方案中，抗ADM抗体或抗-ADM抗体片段或抗-ADM非Ig支架既不会结合N-末端延伸的N-末端修饰的肾上腺髓质素也不结合N-末端降解的肾上腺髓质球蛋白。